Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy
Loading...
Date
2013
Authors
Okwundu, C.I.
Afolabi, B.B.
Journal Title
Journal ISSN
Volume Title
Publisher
Cochrane Database Syst Rev
Abstract
Antibodies to the red cell Rhesus D (RhD) antigen can be produced during pregnancy in a RhD-negative mother carrying a RhDpositive fetus, in particular following feto-maternal haemorrhage at birth or following any procedure that may cause feto-maternal haemorrhage. While the first baby is usually not harmed, these antibodies may cause haemolytic disease of the fetus/newborn (HDFN) in subsequent RhD-positive babies. RhD incompatibility is a major cause of HDFN.
To reduce the risk of HDFN, anti-D is given to RhD-negative mothers at 28 or 30 weeks of pregnancy and within 72 hours of potential maternal exposure to fetal red cells. Anit-D is currently available in both intramuscular (IM) and intravenous (IV) preparations.
Description
Staff Publications
Keywords
Antibodies , Pregnancy , Feto-maternal haemorrhage , Disease , Research Subject Categories::MEDICINE::Surgery::Obstetrics and women's diseases
Citation
Okwundu CI, Afolabi BB. Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD007885. doi: 10.1002/14651858.CD007885.pub2. Review. PubMed PMID: 23440818.